Open AccessAFN-1252, a FabI Inhibitor, Demonstrates a Staphylococcus-Specific Spectrum of Activity
Author(s) -
James A. Karlowsky,
Nachum Kaplan,
Barry Hafkin,
Daryl J. Hoban,
George G. Zhanel
Publication year - 2009
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00400-09
Subject(s) - microbiology and biotechnology , moraxella catarrhalis , staphylococcus aureus , streptococcus pneumoniae , staphylococcus epidermidis , biology , moraxella , enterococcus , bacteria , antibiotics , genetics
AFN-1252, a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibited all clinical isolates ofStaphylococcus aureus (n = 502) andStaphylococcus epidermidis (n = 51) tested, including methicillin (meticillin)-resistant isolates, at concentrations of ≤0.12 μg/ml. In contrast, AFN-1252 was inactive (MIC90 , >4 μg/ml) against clinical isolates ofStreptococcus pneumoniae , beta-hemolytic streptococci,Enterococcus spp.,Enterobacteriaceae , nonfermentative gram-negative bacilli, andMoraxella catarrhalis . These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections.